| FOR MORE
INFORMATION:
American Kennel Club Canine Health
Foundation
Deborah (DD) A. DiLalla, Executive Director
P.O. Box 37941, Raleigh, NC 27627-7941
Phone: 1-888-682-9696 or 919-334-4010
www.akcchf.org
Batten Disease Support and Research Assoc
Lance Johnston, Executive Director
120 Humphries Dr., Suite 2
Reynoldsburg, OH 43068
Phone: 1-800-448-4570 or 740-927-4298
www.bdsra.org
Martin L. Katz, Ph.D
Professor, Ophthalmology, Genetics, Pathobiology, Molecular Biology
Mason Eye
Insititute, University of Missouri School of Medicine
One Hospital Drive, Columbia MO 65212
Phone: 573-882-8480
e-mail:
katzm@health.missouri.edu
Canine Neuronal Ceroid Lipofuscinosis
website |
COLUMBIA, Mo – Dogs are
more than just man’s best friend; at the University of Missouri-Columbia,
dogs are helping with life-saving research. Tibetan Terriers are
contributing to an extensive canine DNA bank in an on-going research
program studying the genetic bases of diseases that affect both dogs and
humans. The Tibetan Terriers can be stricken with a neurological disease,
known as neuronal ceroid lipofuscinosis (NCL), which has a human
equivalent called Batten disease.
NCL diseases are inherited
neurological disorders that have no cure. Though rare, children of parents who
are carriers each have a one in four chance of inheriting the terminal
disease. In order to better understand the pathology of the disease and
develop therapies, Martin Katz, professor of ophthalmology with dual
appointments in the School of Medicine and the College of Veterinary Medicine,
is looking to the Tibetan Terriers for help.
“The purebred dog population
provides an ideal model for genetic research,” said Wayne Ferguson, president
of the American Kennel Club Canine Health Foundation. “The dogs’ pedigrees
provide detailed multigenerational relationship information. The shorter
lifespan of a dog allows researchers to compress studies that would take much
longer with people.”
Katz is searching for the
genetic bases of the disease by studying the large pool of DNA provided by the
dogs’ owners. The normal canine genome, which has been sequenced, is compared
to the DNA of the affected and unaffected Tibetan Terriers to pinpoint the NCL
mutation in this breed. Katz said in order for genetic mapping to be
successful, information about the disease status of the dogs and their
pedigrees must be accurate. Because of the excellent record-keeping by breed
registries and close observations of their dogs by owners, registered purebred
dogs are ideal subjects for genetic studies.
Using the “candidate gene”
approach, Katz sequenced, or identified, the genes of affected Tibetan
Terriers in specific areas thought to be comparable to those where human
markers associated with the condition have been identified. Using this
approach, he was able to eliminate mutations in known NCL genes as the cause
of the Tibetan Terrier disease.
The next step is the
identification of the NCL mutation in Tibetan Terriers. This now requires that
the mutant gene be located through a process called mapping or linkage
analysis. This analysis involves detailed comparison of the DNA from a large
number of affected dogs with the DNA of their parents and affected
littermates.
"The organization of genes in a
genome is like the organization of books in a library,” Katz said. “Genes are
arranged in a specific order on a number of different chromosomes, much like
books are placed in specific orders on specific shelves in a library.
Determining the precise location of a disease-causing mutation within the
genome will identify the disease gene, just as going to a specific location on
a specific shelf in a library will result in a particular book being located.”
Once the NCL mutation in
Tibetan Terriers has been identified, a simple test for the mutation can be
performed on any dog using DNA extracted from a blood sample. This will enable
breeders to screen dogs prior to breeding to prevent generating affected dogs
in the future. Identification of the Tibetan Terrier NCL mutation also will
make it possible to determine whether any humans with NCL have the mutations
in the corresponding human gene.
According to Katz, human NCL
often goes misdiagnosed because the disease is rare and early symptoms overlap
those of other disorders. Eventually, affected children develop an array of
symptoms that include blindness, seizures, cognitive decline and loss of motor
function. Often, it is not until these symptoms are well advanced that a
correct diagnosis is made. Research currently is underway to develop gene and
stem cell therapies for the NCL diseases, but to be effective any therapy will
have to begin early in the course of the disease. Identifying the NCL
mutations will enable definitive diagnoses of these diseases to be made on the
basis of DNA tests early enough to make therapeutic interventions effective.
“Dr. Katz’s work with Tibetan
Terriers has the potential to fast forward the entire research process.” said
Lance Johnson, executive director of the Batten Disease Research and Support
Association. “As we are increasingly able to correlate canine research efforts
with human studies, we expect the crossover opportunities to be phenomenal.”
The Tibetan Terrier DNA bank
was originally conceived and developed by Stuart Eckmann and Linda Bell, who
oversee the Tibetan Terrier Club of America’s health programs. In a
collaborative effort with MU, Eckmann refers owners of affected dogs to Katz
for examination of retinal and neural tissue. The result of this effort has
been a more complete description of the condition than exists in any current
textbook. Using Eckmann’s model, MU has expanded canine DNA banking for
genetic studies to many other dog breeds and diseases including epilepsy,
cancer and Parkinson’s disease.
Support for Katz’s work has
been provided by the American Kennel Club Canine Health Foundation, the Batten
Disease Support and Research Association, and Research to Prevent Blindness,
Inc. Eckmann, Johnston, and Katz presented their collaboration at the 2005
National Parent Club Canine Health Conference held in St Louis, MO, October
21, through October 23, 2005.
|